Making a case for albumin – a highly promising drug-delivery system.
Molecular Pharmacology & Pathology Program, Department of Pathology & Bosch Institute, Blackburn Building, University of Sydney, Sydney, NSW 2006, Australia.
Angelica M
AM
Merlot
Danuta S
DS
Kalinowski
Zaklina
Z
Kovacevic
Patric J
PJ
Jansson
Darius J R
DJ
Lane
Michael L-H
ML
Huang
Sumit
S
Sahni
Des R
DR
Richardson
D000418:Albumins / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy
D000418:Albumins; D000970:Antineoplastic Agents; D004337:Drug Carriers; D007004:Hypoglycemic Agents; D007328:Insulin
albumin; diabetes; drug carriers; drug-delivery; oncology; rheumatoid arthritis